维奈托克用于复发/难治性急性髓系白血病：支持证据充分吗？
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
作者信息
Brancati Serena, Gozzo Lucia, Romano Giovanni Luca, Vetro Calogero, Dulcamare Ilaria, Maugeri Cinzia, Parisi Marina, Longo Laura, Vitale Daniela Cristina, Di Raimondo Francesco, Drago Filippo
机构信息
Clinical Pharmacology Unit, Regional Pharmacovigilance Centre, University Hospital of Catania, 95123 Catania, Italy.
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
出版信息
Cancers (Basel). 2021 Dec 21;14(1):22. doi: 10.3390/cancers14010022.
Abstract
Despite the progress in the development of new therapeutic strategies, relapsed/refractory (R/R) acute myeloid leukemia (AML) still represents a high unmet medical need. Treatment options in this setting include enrollment into clinical trials, allogeneic stem cell transplantation and/or targeted therapy. Nevertheless, it is associated with poor outcomes. Thus, the development of new treatments, which could ameliorate the prognosis of these patients with a good safety profile are highly demanded. Recently, venetoclax (VEN) has been approved for naïve AML patients unfit for intensive chemotherapy. In this regard, regimens including VEN could represent a valuable treatment option even in those with R/R disease and several studies have been conducted to demonstrate its role in this clinical setting. This review aims to summarize the current evidence on the use of VEN regimens in the treatment of R/R AML.
摘要
尽管在新治疗策略的开发方面取得了进展，但复发/难治性（R/R）急性髓系白血病（AML）仍然代表着尚未满足的高度医疗需求。这种情况下的治疗选择包括参加临床试验、异基因干细胞移植和/或靶向治疗。然而，其预后较差。因此，迫切需要开发新的治疗方法，以改善这些患者的预后并具有良好的安全性。最近，维奈克拉（VEN）已被批准用于不适合强化化疗的初治AML患者。在这方面，即使对于R/R疾病患者，包含VEN的治疗方案也可能是一种有价值的治疗选择，并且已经进行了多项研究来证明其在这种临床情况下的作用。本综述旨在总结关于VEN方案用于治疗R/R AML的当前证据。
相似文献
1
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?维奈托克用于复发/难治性急性髓系白血病：支持证据充分吗？
Cancers (Basel). 2021 Dec 21;14(1):22. doi: 10.3390/cancers14010022.
2
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.维奈托克在复发/难治性急性髓系白血病中的作用：过去、现在及未来方向
Bioengineering (Basel). 2023 May 13;10(5):591. doi: 10.3390/bioengineering10050591.
3
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.维奈托克联合低甲基化药物治疗初治 B/髓系混合表型急性白血病和复发/难治性急性髓系白血病：3 例报告。
Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.
4
Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML.维奈克拉联合低甲基化药物及半量CAG方案治疗不适合或难治/复发急性髓系白血病的单中心回顾性临床评估
Onco Targets Ther. 2023 Jun 13;16:409-419. doi: 10.2147/OTT.S405611. eCollection 2023.
5
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting.基于维奈克拉的复发性或难治性急性髓系白血病治疗：2023年美国血液学会年会的最新进展
Exp Hematol Oncol. 2024 Feb 16;13(1):17. doi: 10.1186/s40164-024-00486-7.
6
A retrospective comparison of salvage intensive chemotherapy venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).复发/难治性急性髓系白血病（AML）患者挽救性强化化疗联合维奈克拉方案的回顾性比较
Ther Adv Hematol. 2022 Mar 23;13:20406207221081637. doi: 10.1177/20406207221081637. eCollection 2022.
7
Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.基于维奈托克的复发/难治性急性髓系白血病真实世界治疗方案：一项回顾性单中心经验
J Clin Med. 2021 Apr 14;10(8):1684. doi: 10.3390/jcm10081684.
8
Treatment of Relapsed Acute Myeloid Leukemia.复发急性髓系白血病的治疗。
Curr Treat Options Oncol. 2020 Jun 29;21(8):66. doi: 10.1007/s11864-020-00765-5.
9
Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.维奈托克联合疗法治疗复发/难治性急性髓系白血病：单机构经验
Leuk Res. 2020 Mar;90:106314. doi: 10.1016/j.leukres.2020.106314. Epub 2020 Jan 30.
10
Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?维奈托克联合强化化疗：难治性和/或复发性急性髓系白血病的新希望？
J Clin Med. 2024 Jan 18;13(2):549. doi: 10.3390/jcm13020549.
引用本文的文献
1
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study.复发/难治性急性髓系白血病患者接受维奈托克联合去甲基化药物治疗时，缓解时间是否会影响治疗结果？一项单中心观察性研究的概念验证。
J Clin Med. 2025 Aug 7;14(15):5586. doi: 10.3390/jcm14155586.
2
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.在成人急性髓系白血病中，使用去甲基化药物和维奈托克后进行强化化疗。
Blood Neoplasia. 2024 Aug 28;1(4):100038. doi: 10.1016/j.bneo.2024.100038. eCollection 2024 Dec.
3
A revised prognostic model for patients with acute myeloid leukemia and first relapse.急性髓系白血病首次复发患者的修订预后模型。
Blood Adv. 2025 Aug 12;9(15):3853-3864. doi: 10.1182/bloodadvances.2025015797.
4
The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination.FAT1突变与急性髓系白血病治疗结果的关联，尤其是在接受维奈托克联合治疗时。
Front Oncol. 2025 Mar 31;15:1456832. doi: 10.3389/fonc.2025.1456832. eCollection 2025.
5
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database.法西单抗的不良事件报告：对美国食品药品监督管理局不良事件报告系统（FAERS）数据库的不成比例性分析
Front Pharmacol. 2025 Mar 12;16:1521358. doi: 10.3389/fphar.2025.1521358. eCollection 2025.
6
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.急性髓系白血病中先天和获得性耐药的单细胞全景。
Nat Commun. 2024 Oct 30;15(1):9402. doi: 10.1038/s41467-024-53535-4.
7
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.基于维奈托克的挽救性治疗作为移植的桥梁，对于复发/难治性急性髓系白血病患者是可行且有效的。
Blood Adv. 2025 Jan 28;9(2):375-385. doi: 10.1182/bloodadvances.2024013086.
8
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.意大利药品的早期准入：鲁索替尼用于移植物抗宿主病患者的案例
J Clin Med. 2024 Jul 22;13(14):4273. doi: 10.3390/jcm13144273.
9
characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and PD-1TIM3 exhausted CD8 T cells.对接受低甲基化药物和 venetoclax 方案治疗的急性髓系白血病患者进行表征，揭示了 venetoclax 对非抑制性调节性 T 细胞和 PD-1TIM3 耗尽的 CD8 T 细胞的特异性作用。
Front Immunol. 2024 May 15;15:1386517. doi: 10.3389/fimmu.2024.1386517. eCollection 2024.
10
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病的疗效与安全性：一项多中心真实世界经验
Front Oncol. 2024 Apr 12;14:1370405. doi: 10.3389/fonc.2024.1370405. eCollection 2024.
本文引用的文献
1
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database.维奈托克在急性髓系白血病患者中的超说明书用药：单中心经验及来自药物警戒数据库的数据
Front Pharmacol. 2021 Nov 11;12:748766. doi: 10.3389/fphar.2021.748766. eCollection 2021.
2
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.维奈克拉联合阿扎胞苷和供者淋巴细胞输注治疗异基因造血干细胞移植后复发的急性髓系白血病患者。
Ann Hematol. 2022 Jan;101(1):119-130. doi: 10.1007/s00277-021-04674-x. Epub 2021 Sep 27.
3
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.地西他滨联合维奈托克与强化化疗治疗复发或难治性急性髓系白血病的 10 天疗程：一项倾向评分匹配分析。
Cancer. 2021 Nov 15;127(22):4213-4220. doi: 10.1002/cncr.33814. Epub 2021 Aug 3.
4
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?利妥昔单抗治疗多发性硬化症：我们是否已准备好监管批准？
Front Immunol. 2021 Jul 6;12:661882. doi: 10.3389/fimmu.2021.661882. eCollection 2021.
5
Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting.维奈托克联合基于地西他滨的治疗方案在真实世界中对经过大量前期治疗的复发或难治性急性髓系白血病患者的疗效
Cancer Manag Res. 2021 Jul 12;13:5613-5621. doi: 10.2147/CMAR.S316561. eCollection 2021.
6
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.基于 Venetoclax 的挽救性治疗后联合 Venetoclax 和 DLI 维持治疗与 FLAG-Ida 方案用于异基因造血干细胞移植后复发/难治性急性髓系白血病。
Bone Marrow Transplant. 2021 Nov;56(11):2804-2812. doi: 10.1038/s41409-021-01416-5. Epub 2021 Jul 17.
7
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断和复发/难治性急性髓系白血病。
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
8
Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.基于维奈托克的复发/难治性急性髓系白血病真实世界治疗方案：一项回顾性单中心经验
J Clin Med. 2021 Apr 14;10(8):1684. doi: 10.3390/jcm10081684.
9
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.单中心经验：维奈托克联合治疗初诊和复发的骨髓增生异常相关的 AML。
Blood Adv. 2021 Apr 27;5(8):2156-2164. doi: 10.1182/bloodadvances.2020003934.
10
Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue.儿科癌症女性患者的生育力保存：一个临床和监管问题。
Front Oncol. 2021 Mar 9;11:641450. doi: 10.3389/fonc.2021.641450. eCollection 2021.
Zotero 插件